Results 111 to 120 of about 57,323 (255)
, 2021 Treatment with pharmacological drugs for colorectal cancer (CRC) remains unsatisfactory. A major cause of failure in pharmacotherapy is the resistance of colon cancer cells to the drugs, creating an urgent issue.
Habano, Wataru +3 more
core
International Journal of Cancer, Volume 159, Issue 7, Page 1817-1828, 1 October 2026.Antiangiogenic treatment with ramucirumab is a standard second‐line option in advanced gastric and gastroesophageal junction adenocarcinoma. However, reliable biomarkers are currently lacking. This exploratory biomarker analysis of the RAMIRIS trial suggests that elevated baseline and early on‐treatment levels of the pro‐angiogenic placental growth ...
Jurek Hille +17 more
wiley +1 more source
Impact of Neoadjuvant Approach and Tumor Response on Survival in Pancreatic Adenocarcinoma
Journal of Surgical Oncology, Volume 134, Issue 5, Page 631-638, October 2026.ABSTRACT Introduction Neoadjuvant therapy for pancreatic adenocarcinoma (PDAC) has evolved from single‐agent to multi‐agent approaches, largely informed by metastatic disease studies demonstrating improved survival; albeit at the price of increased toxicity. It remains unclear how response to varied neoadjuvant regimens impact survival. We hypothesized
Mohammed O. Suraju +9 more
wiley +1 more source
Response of small intestinal epithelial cells to irinotecan.
, 2013 (A) Significant decrease in the number of BrdU postive cells in the small intestinal crypts of irinotecan-treated mice. WT mice were injected with PBS (cont) or irinotecan (CPT) for 6 consecutive days and sacrificed on day 7. One hour prior to sacrifice,
Helen Piwnica-Worms (251639) +5 more
core +1 more source
Evasins: Biology and Therapeutic Potential of Broad‐Spectrum Chemokine Inhibitors
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.ABSTRACT Ticks are haematophagous parasites that rely on uninterrupted bloodmeals for survival and need an effective strategy to suppress the host inflammatory response. Leukocyte recruitment is a chemokine‐mediated hallmark of inflammation, which ticks counteract via anti‐chemokine proteins in their saliva named evasins.
Emilia L. Bialek +3 more
wiley +1 more source
CPT: Pharmacometrics & Systems PharmacologyPeritoneal metastases (PM) are common in patients with colorectal cancer. Patients with PM have a poor prognosis, and for those who are not eligible for cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC ...
Pascale C. S. Rietveld +9 more
doaj +1 more source
, 2014 642 Background: Panitumumab and cetuximab are known to be effective in KRAS wild-type metastatic colorectal cancer (mCRC). However, it is not clear whether panitumumab and irinotecan confers benefit that are comparable to those of cetuximab and ...
Yoshitaka Honma +7 more
core +1 more source
Colorectal Disease, Volume 28, Issue 10, October 2026.Abstract Aim Colorectal cancer outcomes are heterogeneous, so greater prognostic discrimination is needed. In this retrospective real‐world analysis, we assessed the prognostic effect of markers of systemic inflammation in a cohort of patients with RAS/BRAF wild‐type metastatic colorectal cancer (mCRC) who received anti‐EGFR therapy during routine care.
Jordan W. Appleyard +10 more
wiley +1 more source
Fruquintinib: Mechanism of Action, Clinical, and Translational Science
Clinical and Translational Science, Volume 19, Issue 10, October 2026.ABSTRACT Fruquintinib is a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3) that was approved, including in China, the United States, and the European Union, for the treatment of previously treated metastatic colorectal cancer (mCRC).
Xiaofei Zhou +7 more
wiley +1 more source